A Standard Intervention Practice to Promote Appropriate Lamotrigine Therapy by Pharmacists

  • Shimamura Hiroshi
    Department of Pharmacy, Showa University Hospital East Branch Division of Biological Chemistry, Department of Molecular Biology, Showa University, School of Pharmacy
  • Yamada Hiroko
    Department of Pharmacy, Showa University Hospital East Branch Department of Hospital Pharmaceutics, Showa University, School of Pharmacy
  • Okada Natsumi
    Department of Hospital Pharmaceutics, Showa University, School of Pharmacy Department of Pharmacy, Showa University Hospital
  • Uchikura Takeshi
    Department of Hospital Pharmaceutics, Showa University, School of Pharmacy
  • Tanaka Katsumi
    Department of Pharmacy, Showa University Hospital
  • Sasaki Tadanori
    Department of Hospital Pharmaceutics, Showa University, School of Pharmacy Department of Pharmacy, Showa University Hospital
  • Itabe Hiroyuki
    Division of Biological Chemistry, Department of Molecular Biology, Showa University, School of Pharmacy

この論文をさがす

抄録

<p>The dosage and frequency of lamotrigine administration for each patient must be prescribed carefully according to the disease, age, concomitant medications, and administration period. According to Pharmaceuticals and Medical Devices Agency (PMDA) reports, either the number of patients with adverse events caused by the inappropriate use of lamotrigine or the ratio of the patients who have benefited from the Relief System for Adverse Drug Reactions did not change even after the revision of the package insert in 2015. The procedure for auditing lamotrigine prescriptions was standardized to improve patient safety in our hospitals. The efficacy of standardization was evaluated by investigating the patients’ records and prescriptions. A total of 77 patients treated with lamotrigine were examined to evaluate the appropriateness of the dosage and frequency of administration as well as the number of prescription enquiries made by pharmacists retrospectively. In addition, the presence of adverse events such as skin rash was examined using medical records. The number of inappropriate cases found and the prescription questions asked by pharmacists during the 24-month period before and after standardization were compared. The rate of inappropriate prescriptions after standardization was significantly lower than that before (12.1 vs. 29%; p<0.05). The rate of prescription questions raised after standardization was significantly higher than that before (37.0 vs. 1.7%; p<0.05). Moreover, there was no adverse event after standardization. Our standardization practice was effective to easily identify inappropriate prescriptions and provide physicians with the appropriate dosage or frequency of administration for the patients.</p>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ